仟源医药(300254.SZ)：拟与关联方等共同向子公司仟源研发增资

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) is accelerating the research and development of precision narcotic drugs through a capital increase in its subsidiary, QianYuan Pharmaceutical Research and Development (Shanghai) Co., Ltd. This move aims to optimize product structure, enhance competitiveness, and motivate the R&D team while managing resources and reducing costs [1] Group 1 - The company, along with professional investors and institutions, is increasing capital in QianYuan R&D, with total contributions amounting to 8.87 million yuan (approximately 1.36 million USD) [1] - The capital increase includes 8 million yuan allocated to registered capital and 800,000 yuan to capital reserves [1] - After the capital increase, QianYuan Pharmaceutical will hold a 30% stake in QianYuan R&D, while other stakeholders will hold varying percentages: Rongliang (20%), Wutong Sanjiang Phase II (10%), Jiangsu Weijia (30%), and QianYuan R&D team (10%) [1]